Andy Lane, M.D., Ph.D.
Dr. Andrew Lane is a Hematology and Medical Oncology fellow at Massachusetts General Hospital and the Dana-Farber Cancer Institute. His main interest is lies in the field of hematopoiesis and the mechanisms by which normal blood cell development is perturbed in malignant diseases of the blood and bone marrow. Using a genetically manipulated bone marrow microenvironment as a tool to modify the stromal-hematopoietic interaction, he is investigating the mechanisms of cooperativity between known hematopoietic mutations associated with human leukemia. The ultimate goal of this work is to develop novel therapies for patients with leukemia, myelodysplastic syndrome, and other hematopoietic diseases.
Andy received his M.D. and Ph.D. degrees from Washington University in 2006, where he studied the PML-RARalpha oncogene in acute promyelocytic leukemia. He was then an intern and resident in internal medicine at Brigham and Women's Hospital. He spent 2008 and 2009 as a clinical fellow in hematology and oncology, finally joining the Scadden Lab in January of 2010.